Stock AnalizBaxter International Inc. BAX
Medical/Dental Instruments · data as of November 13, 2026
Baxter International Inc. (BAX) is a healthcare company listed in the US with a market value of about $13.4B. In the twelve months to September 30, 2026 it had revenue of $11.6B and net income of -$723M, a net margin of -6.2%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 11.8, 5-year revenue growth of -1% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 72% below the current price.
Score: 1.2 / 5
Checks passed
- P/FCF below 20
- Positive free cash flow
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.6B | $11.2B | $10.6B | $10.4B | $10.1B | $12.1B | $11.7B | $11.4B | $11.1B |
| Net income | -$723M | -$957M | -$649M | $2.7B | -$2.4B | $1.3B | $1.1B | $1.0B | $1.5B |
| Free cash flow | $1.1B | $332M | $573M | $1.3B | $834M | $1.5B | $1.2B | $1.4B | $1.4B |
| EPS (diluted) | $-1.42 | $-1.87 | $-1.27 | $5.23 | $-4.83 | $2.53 | $2.13 | $1.93 | $2.83 |
| Net margin | -6.2% | -8.5% | -6.1% | 25.6% | -24.2% | 10.6% | 9.4% | 8.8% | 13.9% |
| ROIC | — | -1.5% | 0.1% | 2.4% | -11.8% | 4.6% | 9.0% | 10.3% | 13.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $27.25, 6% above the current price; targets range from $23.00 to $40.00; the consensus rating is “Hold”; expected EPS is $2.10 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Baxter International stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 72% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Baxter International pay a dividend?
Yes. The dividend yield is about 0.15%, and it has paid dividends for 8 years in our data.
Is Baxter International a good stock to buy?
We do not give buy or sell advice. Baxter International scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.